Teva's Copaxone NDA accepted by FDA for treatment of MS; follow-on Phase III data supportive.
Executive Summary
TEVA COPAXONE NDA ACCEPTED BY FDA for filing, Teva announced Oct. 30. The company resubmitted the NDA Oct. 11 for copolymer-1 for multiple sclerosis with additional chemical information on standards and markers requested by FDA after the agency sent a "refuse to file" letter for the original NDA shortly after it was submitted June 15. Teva disclosed the NDA's status Aug. 21 ("The Pink Sheet" Aug. 28, In Brief).
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth